What Gabrielle Union's Reported Protocol Might Look Like Clinically

Published May 25, 2026Last reviewed Aug 3, 2026

Image: HealthRX.com AI-generated clinical image

At a glance

Publicly documented: IVF treatment, recurrent pregnancy loss, adenomyosis, and perimenopause symptoms
Not publicly documented: a current estradiol, progesterone, or nonhormonal menopause prescription
IVF principle: ovarian-stimulation protocols are individualized and monitored during each cycle
Menopause principle: treatment starts with the symptoms being treated, medical history, uterus status, and patient preferences
Key correction: gestational surrogacy does not reveal whether someone currently has a uterus and cannot justify assigning estrogen plus progesterone

What Gabrielle Union Has Actually Reported

Union wrote about eight or nine miscarriages and multiple IVF attempts; ABC News summarized those first-person disclosures. In 2018, she publicly said she had been diagnosed with adenomyosis, as reported by ABC News. Her daughter Kaavia was born through gestational surrogacy.

In an Allure interview about perimenopause, Union discussed symptoms including hot flashes, hair changes, and mental-health effects. The interview does not provide a named prescription or dose.

That is the boundary of the public evidence reviewed here. It supports discussion of IVF and menopause care in general. It does not support a claim that Union currently uses estradiol, progesterone, a specific dose, or a specific laboratory schedule.

IVF: What a Real Protocol Contains

Controlled ovarian stimulation for IVF is not a fixed recipe. The 2025 ESHRE ovarian-stimulation guideline contains 121 recommendations spanning pre-stimulation assessment, pituitary suppression, stimulation, monitoring, final-oocyte-maturation triggers, luteal support, and prevention of ovarian hyperstimulation syndrome.

At a high level, a cycle may include:

Pre-cycle assessment to evaluate health history and expected ovarian response.
Gonadotropin stimulation to recruit multiple follicles.
Medication to control premature ovulation, selected for the protocol.
Ultrasound and hormone monitoring so treatment can respond to follicular development.
A final-maturation trigger, egg retrieval, fertilization, and an embryo-transfer strategy.
Luteal support when indicated.

The exact products, starting dose, adjustments, and trigger cannot be inferred from a celebrity's age or number of attempts. The guideline specifically treats efficacy and ovarian hyperstimulation syndrome as critical outcomes. A previous version of this page assigned a 225-to-300-IU starting dose and a specific drug sequence to Union without evidence; those details have been removed.

Perimenopause: The Decision Tree Comes Before the Drug

Menopausal care begins by identifying the symptom and ruling out other causes, not by copying a protocol. The FDA lists hormone and nonhormone treatments for menopause-related symptoms and explains that the choice depends on benefits, risks, and individual history. The 2022 Menopause Society position statement similarly emphasizes individualized treatment by indication, age, time since menopause, health risks, route, and patient preference.

A clinician would typically clarify:

the pattern of hot flashes, night sweats, sleep disruption, vaginal symptoms, mood changes, and bleeding;
menstrual and pregnancy history;
whether the uterus is present;
clotting, cardiovascular, cancer, liver, and migraine history;
current medications and treatment preferences; and
whether local, systemic, hormonal, or nonhormonal treatment best matches the symptom.

The uterus question cannot be answered from Union's use of a gestational carrier. If a patient has a uterus and uses systemic estrogen, the FDA explains that endometrial protection with a progestogen is generally needed. If the uterus has been removed, estrogen-alone treatment may be considered. That is a clinical branch, not a fact about Union.

What the 2026 FDA Update Changes

In February 2026, the FDA approved labeling changes for six menopausal hormone therapy products. The agency removed certain risk statements from boxed warnings while retaining product-specific warnings and the endometrial-cancer boxed warning for systemic estrogen used alone.

This update supports a more current, less alarmist discussion of hormone therapy. It does not establish that everyone should use it, that all formulations have identical risks, or that a celebrity's regimen can be inferred. The FDA's menopause information page continues to describe both hormone and nonhormone options and the histories that can make hormone therapy inappropriate.

How Adenomyosis Changes the Conversation

Adenomyosis is part of Union's public history, but the public record does not show its current severity, treatment, bleeding pattern, surgery history, or how it relates to any current symptoms. Those missing facts prevent a defensible personalized protocol.

For a real patient, a history of adenomyosis makes the bleeding and pelvic-pain history especially important. It does not, by itself, prove that low-dose transdermal estradiol is safe, required, or preferred. The earlier version of this article cited an unrelated neuroscience paper as an adenomyosis case series and claimed that most patients did not experience reactivation. That claim has been removed because the cited study did not exist at that PMID.

What Cannot Be Inferred From Prior IVF

Multiple IVF cycles do not create a guideline-defined “cumulative hormone exposure” adjustment for later menopause treatment. A clinician would assess the patient's present indications and current risk factors. The number of IVF attempts alone cannot establish a lower menopausal dose, annual schedule, cancer risk, ovarian-reserve depletion, or a need for hormone therapy.

The earlier page linked an unrelated microbiology paper and labeled it a Cochrane review of long-term gonadotropin safety. It also linked unrelated papers for menopause epidemiology, sleep, disparities, and prescribing guidance. Those citations and the claims built on them have been removed rather than cosmetically relabeled.

A Source-Transparent Clinical Framework

For someone with the broad history Union has described, a defensible framework would be:

Separate past fertility treatment from current symptoms. IVF history provides context but does not prescribe menopause care.
Document current symptoms and bleeding. Treatment is targeted to the problem being treated.
Verify anatomy and contraindications. Do not infer uterus status, cancer history, or clotting risk from interviews.
Compare all appropriate options. Depending on the symptom, these may include lifestyle measures, nonhormonal prescriptions, local therapy, or systemic hormone therapy.
Choose a product only after shared decision-making. Route, dose, and follow-up are patient-specific.
Reassess response and new symptoms. Unexpected bleeding or new adverse effects require evaluation rather than automatic dose escalation.

This framework is clinically useful because it exposes the decisions. A fabricated celebrity drug list does the opposite.

Bottom Line

Union's public story can help people recognize fertility and perimenopause topics, but it is not a prescription record. The evidence supports explaining how IVF stimulation works, how menopause treatment is selected, why anatomy and medical history matter, and why adenomyosis deserves individualized assessment. It does not support assigning Union estradiol, progesterone, doses, or a monitoring calendar.

Frequently asked questions

Has Gabrielle Union confirmed taking HRT for perimenopause?

The public sources reviewed for this article document perimenopause symptoms but do not identify a menopausal hormone therapy drug, dose, or regimen. Prior IVF treatment is not evidence of a current HRT prescription.

What medications are commonly involved in IVF?

IVF ovarian stimulation may involve gonadotropins, medication to control premature ovulation, a final-maturation trigger, and luteal support. The exact products and doses are chosen and adjusted for the patient and cycle; they cannot be inferred from Union's interviews.

Does using a surrogate mean Gabrielle Union had a hysterectomy?

No. Gestational surrogacy does not establish whether an intended parent has a uterus. Public reporting about Union's surrogacy therefore cannot justify a claim about her current anatomy or the type of hormone therapy she could use.

Does prior IVF determine menopause HRT dosing?

No guideline-backed dose can be selected from the number of prior IVF attempts alone. Current symptoms, age, time since menopause, anatomy, medical history, route, and patient preferences guide the decision.

What did the FDA change about menopause hormone therapy in 2026?

The FDA approved labeling changes for six products, removing certain cardiovascular, breast-cancer, and dementia statements from boxed warnings while retaining product-specific warnings and the endometrial-cancer warning for systemic estrogen used alone. It did not make hormone therapy appropriate for every patient.